PR Newswire Clinical TrialsOriginal article
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
PartnershipTfR1 CapX™Positive
AI Analysis
Summary
Apertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX™ technology platform for developing a program to treat Friedreich Ataxia. This partnership grants Lexeo access to next-generation AAV capsids for genetic medicine delivery.
Importance:6/10
Sentiment:
0.60
gene therapypartnershipAAV capsidsrare diseaseFriedreich Ataxia
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 23, 2026 12:00 PM